US Global Jets ETF vs Zimmer Biomet Holdings Inc — how do they compare? US Global Jets ETF trades at $30, while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc pays a 1.07% dividend while US Global Jets ETF pays none, and US Global Jets ETF is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals.
| JETS | ZBH | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $33.34 | $107.71 |
52-Week Low | $23.12 | $79.58 |
Market Cap | — | $17.36B |
Enterprise Value | — | $24.40B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
JETS trades at $30.58, up 0.39% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF faces headwinds from rising fuel costs as U.S. airlines spent $6.66 billion on jet fuel in May 2026 (U.S. Transportation Department, July 2026), though falling oil prices recently provided some relief. Technical indicators show RSI levels in oversold territory at 24.66 for the 12-day period, suggesting potential buying opportunity.
The outlook remains cautious as airline profits face pressure from fuel volatility and Middle East conflict impacts. While lower oil prices offer temporary relief, the sector's cyclical nature and competitive dynamics with defense-focused ETFs present ongoing challenges. Investment opportunity exists for those betting on travel recovery, but risks from fuel price shocks and operational disruptions require careful monitoring.
Zimmer Biomet (ZBH) trades at $89.74, down 1.51% on the day, with a bullish technical signal from moving averages and a consensus price target of $97.67. The company reported revenue of $8.23B in 2025, with net income of $705.10M and a net margin of 8.56%. Recent developments include expansion in Asia Pacific and a planned $1 billion share repurchase program, while Q2 2026 earnings are anticipated on August 5, 2026.
ZBH presents a mixed outlook with strong profitability margins and recent earnings beats offset by declining net income margins and rising debt levels. The stock offers potential upside to analyst targets but faces execution risks in competitive medical markets and macroeconomic pressures on healthcare spending.
Trailing returns across standard periods
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →